NEW FRONTIERS FOR CAR‑T
Dr. Zachary Roberts talks with STAT’s Laura Chang about the potential for CAR T to boost cure rates in early stage disease and overcome access barriers
NEW FRONTIERS FOR CAR‑T
Dr. Zachary Roberts talks with STAT’s Laura Chang about the potential for CAR T to boost cure rates in early stage disease and overcome access barriers
REDEFINING THE FUTURE OF CELL THERAPY WITH OUR AlloCAR T™ PRODUCT PLATFORM
INNOVATION
- Multiplex gene-engineering and gene-editing capabilities
- Proprietary lymphodepletion platform
- State-of-the-art manufacturing
- Opportunity for product optimization
KEY PROGRAMS
- Cemacabtagene ansegedleucel (cema-cel): Frontline treatment in LBCL, including diffuse large B-cell lymphoma (DLBCL)
- ALLO-316: ccRCC
- ALLO-329: autoimmune disease
LEADERSHIP
- A highly experienced management team that includes key pioneers of CAR T cell products
- Singularly focused on the development of AlloCAR T™ products
WE DON’T JUST SEE THE FUTURE.
WE KNOW HOW TO GET THERE.
Our mission is to create and lead the next revolution in cell therapy by delivering to patients the first allogeneic CAR T cell (AlloCAR T™) products for blood cancers, solid tumors and autoimmune disease.
WHY ALLOGENEIC CELL PRODUCTS HAVE THE POTENTIAL TO DO WHAT NO AUTOLOGOUS CAR T HAS DONE BEFORE
ACCESS
- Potential to treat all
eligible patients - Repeat dosing, if needed
- No need for complex logistics
COST
- Scalable and efficient manufacturing
- Potential to treat 100+ patients from a single manufacturing run
- Lower ancillary costs of care
SPEED/RELIABILITY
- "Off-the-shelf" for on-demand treatment
- Less product variability, made from healthy T cells
INNOVATION
- Multiplex
gene-engineering and gene-editing capabilities - Opportunity for product optimization
OUR PARTNERS
